Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 8987 results

  1. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued Reference number: GID-TA10473

  2. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued Reference number: GID-TA10284

  3. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

  4. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued Reference number: GID-TA10546

  5. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

  6. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

  7. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

  8. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

  9. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

  10. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

  11. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

  12. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

  13. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

  14. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

  15. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320